Andere Sprachen Caplin Point Laboratories Limited NSE India S.E.

Aktien

A2DSTM

INE475E01026

CAPLIPOINT

Markt geschlossen - NSE India S.E. Andere Börsenplätze 13:40:29 16.07.2024			% 5 Tage	% 1. Jan.
1 534 ^INR	+0,96 %		-0,09 %	+13,11 %

11.06.	Caplin Point Laboratories Limited ernennt Thiagaraja Manikandan zum Chief Transformation & Digital Officer	CI
24.05.	Caplin Point Arm erhält grünes Licht der US FDA für Phenylephrinhydrochlorid-Augenarzneimittel	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer	11.06.
Caplin Point Arm Gets US FDA's Nod for Phenylephrine Hydrochloride Ophthalmic Solution	24.05.
Caplin Point Laboratories to Seek Acquisitions	16.05.
Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024	16.05.
Caplin Point Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	16.05.
Caplin Point Laboratories Gets Colombian Drug Regulator's Approval for Soft Gel Capsules Unit in India	06.05.
Caplin Point Laboratories Limited Receives Colombia's INVIMA Approval for Its Softgel Capsules Division At Puducherry	06.05.
Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution	16.04.
Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication	28.03.
Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution	28.03.
Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India	27.03.
Caplin One Labs Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited Successfully Completes New Oncology (Anti-Cancer) Facility, Commences Operations	27.03.
Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09.02.
Caplin Point Laboratories to Invest INR7 Billion in Tamil Nadu, India	08.01.
Caplin Point Unit Gets US FDA Final Approval for Generic Ear Infection Drug	08.01.
Caplin Point Laboratories Limited Announces Resignation of Hero Velladurai as President, R&D	14.12.
Caplin Point Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09.11.
Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023	22.09.23
Caplin Point Unit's Injectable and Ophthalmic Plant in India Gets VAI Classification from US FDA	04.09.23
Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	07.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Caplin Point Laboratories Limited NSE India S.E.

Aktien

A2DSTM

INE475E01026

CAPLIPOINT

Andere Sprachen

Filter